The revival of fosfomycin

International Journal of Infectious Diseases

Volumn 15, Issue 11, 2011, Pages

  Michalopoulos, Argyris S ^a   Livaditis, Ioannis G ^a   Gougoutas, Vassilios ^a  

^a HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Enterococcus faecalis; Escherichia coli; Klebsiella pneumoniae; Nosocomial infections; Pseudomonas aeruginosa; Urinary tract infections

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BACTERIAL ENZYME; BALSALAZIDE; BETA LACTAM ANTIBIOTIC; BILIRUBIN; FOSFOMYCIN; FOSFOMYCIN CALCIUM; FOSFOMYCIN SODIUM; FOSFOMYCIN TROMETAMOL; GLUCOSE 6 PHOSPHATE; GLUTATHIONE TRANSFERASE; GLYCEROPHOSPHATE; HEMOGLOBIN; HEXOSE PHOSPHATE; METALLOGLUTATHIONE TRANSFERASE; METOCLOPRAMIDE; MURAMIC ACID; N ACETYLMURAMIC ACID; PEPTIDOGLYCAN; PYRUVATE SYNTHASE; PYRUVATE WATER DIKINASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSCESS; AGAR DILUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BACTERIAL CELL; BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; BILIRUBIN BLOOD LEVEL; BIOFILM; BRAIN VENTRICULITIS; BROTH DILUTION; CHRONIC KIDNEY FAILURE; CITROBACTER; COVALENT BOND; CYSTITIS; DIARRHEA; DISK DIFFUSION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG URINE LEVEL; DYSPEPSIA; ENTEROBACTER; ENTEROCOCCUS; ENZYME INHIBITION; EOSINOPHIL COUNT; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; GRAM POSITIVE INFECTION; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL INFECTION; HUMAN; HYPEREOSINOPHILIA; HYPERTENSION; HYPOKALEMIA; IMMUNOMODULATION; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; KLEBSIELLA PNEUMONIAE; LEUKOCYTE COUNT; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEISSERIA MENINGITIDIS; NEUTROPENIA; PHARYNGITIS; POSTOPERATIVE INFECTION; PREGNANCY DISORDER; PREOPERATIVE TREATMENT; PROTEIN SYNTHESIS INHIBITION; PROTEUS MIRABILIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; RHINITIS; SALMONELLA TYPHI; SERRATIA MARCESCENS; SHIGELLA; SIDE EFFECT; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE COUNT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VAGINITIS; WEAKNESS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FOSFOMYCIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA PNEUMONIAE; PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTIONS;

EID: 80054954865     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.07.007     Document Type: Review

References (114)

1. Hendlin D., Stapley E.O., Jackson M., Wallick H., Miller A.K., Wolf F.J., et al. Phosphonomycin. A new antibiotic produced by strains of Streptomyces. Science 1969, 166:122-123.
2. Falagas M.E., Giannopoulou K.P., Kokolakis G.N., Rafailidis P.I. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008, 46:1069-1077.
3. Woodruff H.B., Mata J.M., Hernández S., Mochales S., Rodríguez A., Stapley E.O., et al. Fosfomycin: laboratory studies. Chemotherapy 1977, 23(Suppl 1):1-22.
4. Suárez J.E., Mendoza M.C. Plasmid-encoded fosfomycin resistance. Antimicrob Agents Chemother 1991, 35:791-795.
5. Kahan F.M., Kahan J.S., Cassidy P.J., Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974, 235:364-386.
6. Takahashi K., Kanno H. Synergistic activities of combination of beta lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984, 26:789-791.
7. Chin N.X., Neu N.M., Neu H.C. Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic Gram-negative bacilli. Drugs Exp Clin Res 1986, 12:943-947.
8. Okazaki M., Suzuki K., Asano N., Araki K., Shukuya N., Egami T., et al. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 2002, 8:37-42.
9. Grayson M.L. Kucers' the use of antibiotics 2010, Hodder Arnold, Melbourne, Australia. 6th ed.
10. Segre G., Bianchi E., Cataldi A., Zannini G. Pharmacokinetic profile of fosfomycin trometamol (Monuril). Eur Urol 1987, 13(Suppl 1):56-63.
11. Joukhadar C., Klein N., Dittrich P., Zeitlinger M., Geppert A., Skhirtladze K., et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003, 51:1247-1252.
12. Legat F.J., Maier A., Dittrich P., Zenahlik P., Kern T., Nuhsbaumer S., et al. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother 2003, 47:371-374.
13. Matzi V., Lindenmann J., Porubsky C., Kugler S.A., Maier A., Dittrich P., et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010, 65:995-998.
14. Schintler M.V., Traunmüller F., Metzler J., Kreuzwirt G., Spendel S., Mauric O., et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 2009, 64:574-578.
15. Frossard M., Joukhadar C., Erovic B.M., Dittrich P., Mrass P.E., Van Houte M., et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother 2000, 44:2728-2732.
16. Sauermann R., Karch R., Langenberger H., Kettenbach J., Mayer-Helm B., Petsch M., et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother 2005, 49:4448-4454.
17. Kuhnen E., Pfeifer G., Frenkel C. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection 1987, 15:422-424.
18. Sauermann R., Schwameis R., Fille M., Ligios M.L., Zeitlinger M. Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. J Antimicrob Chemother 2009, 64:821-823.
19. Gobernado M. Fosfomycin. Rev Esp Quimioter 2003, 16:15-40.
20. Pfausler B., Spiss H., Dittrich P., Zeitlinger M., Schmutzhard E., Joukhadar C. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 2004, 53:848-852.
21. Falagas M.E., Maraki S., Karageorgopoulos D.E., Kastoris A.C., Kapaskelis A., Samonis G. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents 2010, 35:497-499.
22. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. 20th informational supplement 2010, CLSI, Wayne, PA.
23. de Cueto M., Lopez L., Hernandez J.R., Morillo C., Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006, 50:368-370.
24. Ribes S., Taberner F., Domenech A., Cabellos C., Tubau F., Liñares J., et al. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006, 57:931-936.
25. Banon Arias R., Garcia Lopez M., Pinedo Sanchez A. Time-kill evaluation of antimicrobial regimens against clinical isolates of penicillin-resistant Streptococcus pneumoniae. J Chemother 2001, 13:535-540.
26. Mastouri M., Nour M., Ben Nejma M., Bouallegue O., Hammami M., Khedher M. Antibiotics resistance of methicillin-resistant Staphylococcus aureus: detection of the first glycopeptides low sensibility strains in Tunisia. Pathol Biol (Paris) 2006, 54:33-36.
27. Allerberger F., Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999, 43:211-217.
28. Barry A.L., Brown S.D. Antibacterial spectrum of fosfomycin trometamol. J Antimicrob Chemother 1995, 35:228-230.
29. de Cueto M., Hernández J.R., López-Cerero L., Morillo C., Pascual A. Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Enferm Infecc Microbiol Clin 2006, 24:613-616.
30. Falagas M.E., Kastoris A.C., Karageorgopoulos D.E., Rafailidis P.I. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009, 34:111-120.
31. Martinez-Martinez L., Rodriguez G., Pascual A., Suárez A.I., Perea E.J. In vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1996, 38:1107-1108.
32. Pruekprasert P., Tunyapanit W. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa. Southeast Asian J Trop Med Public Health 2005, 36:1239-1242.
33. Mirakhur A., Gallagher M.J., Ledson M.J., Hart C.A., Walshaw M.J. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003, 2:19-24.
34. Altés Gutiérrez A., Rodríguez Noriega A. In vitro sensitivity of anaerobic bacteria to fosfomycin. Chemotherapy 1977, 23(Suppl 1):51-57.
35. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10:43-50.
36. Tharavichitkul P., Khantawa B., Bousoung V., Boonchoo M. Activity of fosfomycin against extended-spectrum-β-lactamase producing Klebsiella pneumoniae and Escherichia coli in Maharaj Nakorn Chiang Mai Hospital. J Infect Dis Antimicrob Agents 2005, 22:121-126.
37. Giakkoupi P., Xanthaki A., Kanelopoulou M., Vlahaki A., Miriagou V., Kontou S., et al. VIM-1 Metallo-beta-lactamase producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 2003, 41:3893-3896.
38. Endimiani A., Patel G., Hujer K.M., Swaminathan M., Perez F., Rice L.B., et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those non-susceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010, 54:526-529.
39. Samonis G., Maraki S., Rafailidis P.I., Kapaskelis A., Kastoris A.C., Falagas M.E. Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials. Future Microbiol 2010, 5:961-970.
40. Rodríguez-Martínez J.M., Ballesta S., Pascual A. Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms. Int J Antimicrob Agents 2007, 30:366-368.
41. Monden K., Ando E., Iida M., Kumon H. Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm. J Infect Chemother 2002, 8:218-226.
42. Mikuniya T., Kato Y., Ida T., Maebashi K., Monden K., Kariyama R., et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 2007, 13:285-290.
43. Cai Y., Fan Y., Wang R., An M.M., Liang B.B. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J Antimicrob Chemother 2009, 64:563-566.
44. Kusachi S., Nagao J., Saida Y., Watanabe M., Okamoto Y., Asai K., et al. Antibiotic time-lag combination therapy with fosfomycin for postoperative intra-abdominal abscesses. J Infect Chemother 2011, 17:91-96.
45. Etienne J., Gerbaud G., Courvalin P., Fleurette J. Plasmid-mediated resistance to fosfomycin in Staphylococcus epidermidis. FEMS Microbiol Lett 1989, 52:133-137.
46. Beharry Z., Palzkill T. Functional analysis of active site residues of the fosfomycin resistance enzyme FosA from Pseudomonas aeruginosa. J Biol Chem 2005, 280:17786-17791.
47. Horii T., Kimura T., Sato K., Shibayama K., Ohta M. Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother 1999, 43:789-793.
48. García P., Arca P., Toyos J.R., Suárez J.E. Detection of fosfomycin resistance by the polymerase chain reaction and Western blotting. J Antimicrob Chemother 1994, 34:955-963.
49. Arca P., Rico M., Braña A.F., Villar C.J., Hardisson C., Suárez J.E. Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother 1988, 32:1552-1556.
50. Arca P., Hardisson C., Suarez J.E. Purification of a glutathione S-transferase that mediates fosfomycin resistance in bacteria. Antimicrob Agents Chemother 1990, 34:844-848.
51. Cao M., Bernat B.A., Wang Z., Armstrong R.N., Helmann J.D. FosB, a cysteine-dependent fosfomycin resistance protein under the control of sigma(W), an extracytoplasmic-function sigma factor in Bacillus subtilis. J Bacteriol 2001, 183:2380-2383.
52. Bernat B.A., Laughlin L.T., Armstrong R.N. Fosfomycin resistance protein (FosA) is a manganese metalloglutathione transferase related to glyoxalase I and the extradiol dioxygenases. Biochemistry 1997, 36:3050-3055.
53. Rigsby R.E., Fillgrove K.L., Beihoffer L.A., Armstrong R.N. Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily. Methods Enzymol 2005, 401:367-379.
54. Arca P., Reguera G., Hardisson C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother 1997, 40:393-399.
55. Reeves D. Fosfomycin trometamol. J Antimicrob Chemother 1994, 34:853-858.
56. Gold H.S. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001, 33:210-219.
57. Jones R.N., Anderegg T.R., Swenson J.M. Quality control guidelines for testing Gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J Clin Microbiol 2005, 43:925-927.
58. Rudenko N., Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung 2005, 55:420-427.
59. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010, 65:1862-1877.
60. Pullukcu H., Tasbakan M., Sipahi O.R., Yamazhan T., Aydemir S., Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007, 29:62-65.
61. Rodríguez-Baño J., Alcalá J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008, 168:1897-1902.
62. Stein G.E. Fosfomycin tromethamine: single-dose treatment of acute cystitis. Int J Fertil Womens Med 1999, 44:104-109.
63. Schito G.C. Why fosfomycin trometamol as first line therapy for uncomplicated UTI?. Int J Antimicrob Agents 2003, 22(Suppl 2):79-83.
64. Souli M., Galani I., Antoniadou A., Papadomichelakis E., Poulakou G., Panagea T., et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010, 50:364-373.
65. Michalopoulos A., Virtzili S., Rafailidis P., Chalevelakis G., Damala M., Falagas M.E. Intravenous fosfomycin for the treatment of nosocomial infections due to carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010, 16:184-186.
66. Yamaguchi Y., Hanaki H., Yanagisawa C., Ikeda-Dantsuji Y., Hashimoto T., Yazaki H., et al. Characterization of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration. J Infect Chemother 2009, 15:274-278.
67. Forestier F., Salvanet-Bouccara A., Leveques D., Junes P., Rakotondrainy C., Dublanchet A., et al. Ocular penetration kinetics of fosfomycin administered as a one-hour infusion. Eur J Ophthalmol 1996, 6:137-142.
68. Popovic M., Steinort D., Pillai S., Joukhadar C. Fosfomycin: an old, new friend?. Eur J Clin Microbiol Infect Dis 2010, 29:127-142.
69. Meissner A., Haag R., Rahmanzadeh R. Adjuvant fosfomycin medication in chronic osteomyelitis. Infection 1989, 17:146-151.
70. Florent A., Chichmanian R.M., Cua E., Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011, 37:82-83.
71. Alvarez R., Adan A., Martinez J.A., Casale A., Miro J.M. Haematogenous Serratia marcescens endophthalmitis in an HIV-infected intravenous drug addict. Infection 1990, 18:29-30.
72. Boulard G., Quentin C., Scontrini G., Dautheribes M., Pouguet P., Sabathie M. Treatment of ventriculitis caused by Staphylococcus epidermidis on equipment with the combination of fosfomycin and an aminoglycoside. Course of ventricular levels of fosfomycin. Pathol Biol (Paris) 1983, 31:525-527.
73. Bureau-Chalot F., Piednoir E., Bazin A., Brasme L., Bajolet O. Postoperative spondylodiskitis due to Stomatococcus mucilaginosus in an immunocompetent patient. Scand J Infect Dis 2003, 35:146-147.
74. Gillard J., Boutoille D., Varin S., Asseray N., Berthelot J.M., Maugars Y. Suspected disk space infection with negative microbiological tests-report of eight cases and comparison with documented pyogenic discitis. Joint Bone Spine 2005, 72:156-162.
75. Guerin F., Henegar C., Spiridon G., Launay O., Salmon-Ceron D., Poyart C. Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-β-lactamase gene from Saudi Arabia. J Antimicrob Chemother 2005, 56:601-602.
76. May T., Weber M., Gérard A., Schmit J.L., Voiriot P., Czorny A., et al. Treatment of post-traumatic and post-neurosurgical bacterial meningitis with ceftriaxone alone or in combination with fosfomycin. Pathol Biol (Paris) 1987, 35(5 Pt 2):839-842.
77. Nakayama M., Tsunoda K., Igarashi M., Nishikawa K., Okazaki K. A case of toxic shock syndrome induced by MRSA after sinus surgery. Masui 1996, 45:994-997.
78. Nissen L.R., Jacobsen J., Ravn T.J., Wahlgreen C., Auning-Hansen H. Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia. Infection 1986, 14:246-249.
79. Ortler M., Luef G., Kofler A., Bauer G., Twerdy K. Deep wound infection after vagus nerve stimulator implantation: treatment without removal of the device. Epilepsia 2001, 42:133-135.
80. Portier H., Kazmierczak A., Lucht F., Tremeaux J.C., Chavanet P., Duez J.M. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection 1985, 13(Suppl 1):S123-S128.
81. Roualdes G., Lartigue C., Boudigue M.D., Maissin F. Infection of the valves of CSF shunts: results of local and general antibiotic treatment in 6 cases. Neurochirurgie 1985, 31:390-394.
82. Silbermann M.H., Gyssens I.C., Wielenga J.J., Endtz H.P., Löwenberg B. A patient with acute leukemia and meningitis caused by Staphylococcus epidermidis treated with fosfomycin. Ned Tijdschr Geneeskd 1995, 139:2498-2501.
83. Ueda T., Masaoka T., Shibata H., Nagai K., Kanamaru A., Horiuchi A., et al. Clinical evaluation of high dose intravenous injection of fosfomycin on the severe infections associated with the treatment of haematological disorders. Jpn J Antibiot 1983, 36:311-315.
84. Zink P.M., Schick D., Trappe A.E. Non-surgical management of an infected ventriculo-atrial shunt. Neurochirurgia (Stuttg) 1989, 32:61-64.
85. Ishizaka K., Kobayashi S., Machida T., Yoshida K. Randomized prospective comparison of fosfomycin and cefotiam for prevention of postoperative infection following urological surgery. J Infect Chemother 2007, 13:324-331.
86. Andåker L., Burman L.G., Eklund A., Graffner H., Hansson J., Hellberg R., et al. Fosfomycin/metronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective colorectal surgery: a randomised double-blind multicentre trial in 517 patients. Eur J Surg 1992, 158:181-185.
87. Andåker L., Höjer H., Kihlström E., Lindhagen J. Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir Scand 1987, 153:185-192.
88. Lebreton P., Vergnaud M., Zerr C., Nigam M., Kaladji C., Quesnel J. Antibiotic prophylaxis using a combination of pefloxacin and fosfomycin in heart surgery with CEC (extracorporeal circulation) in patients allergic to beta-lactams. Cah Anesthesiol 1989, 37:77-87.
89. Lindhagen J., Andåker L., Höjer H. Comparison of systemic prophylaxis with metronidazole/placebo and metronidazole/fosfomycin in colorectal surgery. A clinical study demonstrating the need for additional anti-aerobic prophylactic cover. Acta Chir Scand 1984, 150:317-323.
90. Nøhr M., Andersen J.C., Juul-Jensen K.E. Prophylactic single-dose fosfomycin and metronidazole compared with neomycin, bacitracin, metronidazole and ampicillin in elective colorectal operations. Acta Chir Scand 1990, 156:223-230.
91. Shinagawa N., Mizuno I., Fukui T., Takeyama H., Yasuda A., Matsumoto K., et al. Prophylactic effect of fosfomycin on postoperative infection in gastroenterological surgery. Jpn J Antibiot 2006, 59:417-427.
92. Sánchez-Morillas L., Pérez-Ezquerra P.R., Reaño-Martos M., Mayorga C., Laguna-Martínez J.J. Anaphylaxis induced by fosfomycin. Ann Allergy Asthma Immunol 2010, 105:241.
93. Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997, 53:637-656.
94. Bedirdjian J.P., Morin J.P., Fouchet B., Fillastre J.P. Effect of fosfomycin on respiration by rat kidney mitochondria. Minerva Med 1978, 69:4079-4086.
95. Mayama T., Yokota M., Shimatani I., Ohyagi H. Analysis of oral fosfomycin calcium (Fosmicin) side-effects after marketing. Int J Clin Pharmacol Ther Toxicol 1993, 31:77-82.
96. Available at: [accessed day September 15, 2011]. http://www.drugs.com/drug-interactions/fosfomycin.html.
97. Ferrara A., Dos Santos C., Cimbro M., Gialdroni Grassi G. Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci. Eur J Clin Microbiol Infect Dis 1997, 16:535-537.
98. Komatsuzawa H., Suzuki J., Sugai M., Miyake Y., Suginaka H. Effect of combination of oxacillin and non-beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1994, 33:1155-1163.
99. Sahuquillo Arce J.M., Colombo Gainza E., Gil Brusola A., Ortiz Estévez R., Cantón E., Gobernado M. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin susceptible Staphylococcus aureus. Rev Esp Quimioter 2006, 19:252-257.
100. Rice L.B., Eliopoulos C.T., Yao J.D., Eliopoulos G.M., Moellering R.C. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn Microbiol Infect Dis 1992, 15:173-176.
101. Yu X.H., Song X.J., Cai Y., Liang B.B., Lin D.F., Wang R. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo) 2010, 63:657-659.
102. Olay T.A., Rodriguez A., Oliver L.E., Vicente M.V., Quecedo M.C. Interaction of fosfomycin with other antimicrobial agents: in vitro and vivo studies. J Antimicrob Chemother 1978, 4:569-576.
103. Hayami H., Goto T., Kawahara M., Ohi Y. Activities of β-lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination against Pseudomonas aeruginosa isolated from complicated urinary tract infections. J Infect Chemother 1999, 5:130-138.
104. Roussos N., Karageorgopoulos D.E., Samonis G., Falagas M.E. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. J Antimicrob Agents 2009, 34:506-515.
105. Morikawa K., Oseko F., Morikawa S., Sawada M. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1993, 37:2684-2687.
106. Honda J., Okubo Y., Kusaba M., Kumagai M., Saruwatari N., Oizumi K. Fosfomycin (FOM: 1 R-2S-epoxypropylphosphonic acid) suppress the production of IL-8 from monocytes via the suppression of neutrophil function. Immunopharmacology 1998, 39:149-155.
107. Matsumoto T., Tateda K., Miyazaki S., Furuya N., Ohno A., Ishii Y., et al. Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 1997, 41:308-313.
108. Morikawa K., Watabe H., Araake M., Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 1996, 40:1366-1370.
109. Morikawa K., Zhang J., Nonaka M., Morikawa S. Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002, 19:53-59.
110. Matsumoto T., Tateda K., Miyazaki S., Furuya N., Ohno A., Ishii Y., et al. Fosfomycin alters lipopolysaccharide-induced inflammatory cytokine production in mice. Antimicrob Agents Chemother 1999, 43:697-698.
111. Sauermann R., Marsik C., Steiner I., Seir K., Cvitko T., Zeitlinger M., et al. Immunomodulatory effects of fosfomycin in experimental human endotoxemia. Antimicrob Agents Chemother 2007, 51:1879-1881.
112. Pérez Fernández P., Herrera I., Martínez P., Gómez-Lus M.L., Prieto J. Enhancement of the susceptibility of Staphylococcus aureus to phagocytosis after treatment with fosfomycin compared with other antimicrobial agents. Chemotherapy 1995, 41:45-49.
113. Tullio V., Cuffini A.M., Banche G., Mandras N., Allizond V., Roana J., et al. Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli. Int J Immunopathol Pharmacol 2008, 21:153-160.
114. Krause R., Patruta S., Daxböck F., Fladerer P., Wenisch C. The effect of fosfomycin on neutrophil function. J Antimicrob Chemother 2001, 47:141-146.